https://vitasmlab.net

FILOMARK

Filoviruses Targeted Library

Human filoviruses, including Ebola virus, are among the most lethal pathogens known, causing severe hemorrhagic fever with case fatality rates up to 90%. They disrupt immune responses, cause vascular leakage, and lead to multi-organ failure, often outpacing any therapeutic intervention. While outbreaks are sporadic, their potential for rapid human-to-human trans- mission and high mortality makes them a critical biosecurity threat. Current treatments are largely supportive, with few approved therapies limited to emergency use and logistical constraints. There is a pressing need for novel small molecule drugs that are orally bioavailable, stable, and broadly effective across filovirus species. Such agents could target viral entry, replication, or host pathways to improve outcomes, especially in resource-limited settings. Developing accessible antivirals is essential to contain future outbreaks, reduce mortality, and strengthen pandemic preparedness against this high-conse- quence viral family.





STK437874



STK439077



STK330877

Filoviruses Targeted Library (FILOMARK) contains compounds with potential anti-filoviral activity, which were selected based on similarity to known effectors of vital viral processes such as RNA synthesis and host entry. This library was designed to provide a potential starting point or to expand ongoing drug discovery project. It is designed in a way that maximizes structural diversity and excludes problematic compounds. This library has 1778 compounds. All compounds follow RO5.

Distribution of Parameters



If you have any specific needs for your project, we can provide specially tailored compound library based on your request.

Have questions or need a quote? Contact Irina Haywood (Ryabushenko) at

irina@vitasmlab.biz

Let's Connect on LinkedIn! Expand your professional network.

We look forward to collaborating with you!

Empowering Your Research, One Molecule at a Time.